RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin

The combination of gemcitabine plus cisplatin (GP) is regarded as a first-line treatment for patients with unresectable or recurrent biliary tract cancer (BTC). Several proteins including human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (DCK), cytidine deaminase (CDA), and...

Full description

Bibliographic Details
Main Authors: Jung Won Chun, Boyoung Lee, Weon Seo Park, Nayoung Han, Eun Kyung Hong, Eun Young Park, Sung Sik Han, Sang-Jae Park, Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Journal of Clinical Medicine
Subjects:
biliary tract neoplasms
cisplatin
gemcitabine
ribonucleotide reductases
Online Access:https://www.mdpi.com/2077-0383/10/20/4652

Internet

https://www.mdpi.com/2077-0383/10/20/4652

Similar Items